Encellin develops a novel thin-film cell encapsulation device for cell-based therapeutics.
Encellin has raised $2.5M in total funding. The most recent round was Grant. The last funding was announced in September 2026.
Encellin's investors include Khosla Ventures, Y Combinator, Breakthrough T1D, Endurance28, Sand Hill Angels.
Encellin is headquartered in San Francisco, United States.
Encellin develops a novel thin-film cell encapsulation device for cell-based therapeutics.
Encellin is at the Grant stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"Encellin — Funding & Investors." VCBacked, September 22, 2026, https://www.vcbacked.co/company/encellin. Accessed October 14, 2026.
VCBacked. (2026). Encellin — Funding & Investors. Retrieved October 14, 2026, from https://www.vcbacked.co/company/encellin
{{cite web |title=Encellin — Funding & Investors |url=https://www.vcbacked.co/company/encellin |website=VCBacked |access-date=October 14, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated